Genetic Signatures Limited (ASX:GSS)
Australia · Delayed Price · Currency is AUD 0.0780
+0.0080 (11.43%)
Jun 5, 2026, 4:10 PM AEST
Hemas Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Revenue rose slightly to AUD 8.7 million, but gross margin declined due to higher costs. U.S. expansion remains a focus, with new customers and product development underway, while a forensic review targets cost reductions to address high cash burn.
Fiscal Year 2025
-
Revenue grew 63% to $15.9M with gross margin at 55%, driven by strong respiratory and EMEA sales. Strategic refocus, new automation partnerships, and disciplined cost management position the company for future growth despite a $20.1M loss and slower U.S. uptake.
-
Sales rose 136% year-over-year, with gross margin up to 59% and a statutory loss impacted by a one-time impairment. The first U.S. contract was secured, a strong pipeline is in place, and cash reserves exceed AUD 40.7 million.